LXEO (Lexeo Therapeutics, Inc.) רווח למניה בארבעת הרבעונים האחרונים

Lexeo Therapeutics (LXEO) is strengthening its position through proprietary treatments for cardiomyopathies and Alzheimer's disease, while adhering to strict bioethical norms and ESG standards. This chart on the GURU.Markets platform shows that EPS (TTM) is 64.30. The business relies on the development of gene therapies for cardiac pathologies, allowing the company to implement premium pricing for unique, one-time curative sessions.
Lexeo Therapeutics - פילוחים אנליטיים ומדדי מפתח (LXEO)

Investors must find a balance between the high operational risks of biopharmaceuticals and the potential return on capital. Lexeo Therapeutics (LXEO) focuses on correcting genetic DNA defects using proprietary AAV vectors. The year-over-year EPS trend (trailing 12 months) reflects the rate of change in net income per share, allowing for an assessment of the efficiency of development monetization. Steady growth of this indicator confirms the business's financial stability during the clinical trial period.